標的治療薬の世界市場

標的治療薬の世界市場は2030年までに1,118億米ドルに達する見込み

2024年に805億米ドルと推定される標的治療薬の世界市場は、2024年から2030年にかけてCAGR 5.6%で成長し、2030年には1,118億米ドルに達すると予測されます。本レポートで分析したセグメントの一つであるモノクローナル抗体は、CAGR6.7%を記録し、分析期間終了時には739億米ドルに達すると予想されます。低分子セグメントの成長率は、分析期間中CAGR 3.7%と推定されます。

米国市場は219億米ドルと推定、中国はCAGR 9.1％で成長すると予測

米国の標的治療薬市場は2024年に219億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに228億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは9.1%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.7%と5.6%と予測されています。欧州では、ドイツがCAGR 3.7%で成長すると予測されています。

世界の標的治療薬市場- 主要動向と促進要因のまとめ

標的治療薬の躍進要因とは？

標的治療薬とは、疾患細胞で特異的に発現または変化している分子または経路と特異的に相互作用するように設計され、標的外影響を最小限に抑える治療法を指します。これには、モノクローナル抗体、低分子阻害剤、抗体薬物複合体（ADC）、選択的プロモーターを持つ遺伝子治療ベクター、RNA治療薬やペプチドワクチンのような新しい治療法が含まれます。プレシジョン・メディシン・イニシアチブ、マルチオミクス・プロファイリング、コンパニオン・ダイアグノスティックスは、特定の患者集団に合わせた薬剤開発パイプラインをサポートします。製薬会社は、ドライバー変異（EGFR、ALK、BRAFなど）、エピジェネティック制御因子、免疫チェックポイントを標的とした、これまで以上に選択性の高い化合物を開発しています。製造の複雑さと規制の厳しさは依然として高いが、スケーラブルなモジュラープラットフォームと適応性のある臨床試験デザインにより、市場投入までの時間は短縮されています。

革新はどこで標的薬の限界を押し広げるのか？

革新的な分野の一つは、腫瘍抗原と免疫エフェクターを同時に結合できる二重特異性抗体です。鎌状赤血球症などの体細胞変異をターゲットとするCRISPRベースの遺伝子編集療法は、mRNA脂質ナノ粒子プラットフォームによって組織特異的デリバリーが可能となり、治療的アプローチとして目覚めつつあります。診断の進化-液体生検、デジタル液滴PCR、シングルセルRNA-seq-は、リアルタイムのモニタリングと適応的な投与計画を可能にしています。AIによる標的予測を用いた計算薬物設計は、創薬のタイムラインを短縮しています。電子カルテへの薬理ゲノミクスの統合は、実用的な処方を促進し、高価な副作用の回避に役立っています。

エンドユーザーのニーズはどのように治療戦略を形成しているか？

がん専門医は、抵抗性を克服し治療成績を改善するために、標的薬と免疫療法の併用レジメンを好んでいるが、そのためには薬物間相互作用やバイオマーカーに基づいた治療を慎重に検討する必要があります。希少疾患コミュニティは、超希少な標的治療薬への需要を促進し、規制当局に承認の迅速化と希少疾病用医薬品開発の奨励を促しています。皮下ADC、在宅注射可能なキナーゼ阻害剤、デジタル・アドヒアランス・システムなど、患者中心の投与方法が普及しつつあります。市販後の実臨床データによるエビデンスの創出が支払側の受容性をさらに形成し、医薬品開発企業は価値に基づく契約やアウトカム登録への投資を求められます。新興市場では、段階的価格設定と地域診断ラボを採用し、標的薬へのアクセスギャップを埋めています。

標的治療薬急増の要因は？

標的治療薬市場の成長は、腫瘍や遺伝性疾患の負担の増加、バイオマーカー主導の臨床経路の広範な採用、高度なドラッグデリバリープラットフォームの統合など、いくつかの要因によって牽引されています。スケーラブルなRNAや細胞治療の製造が登場したことで、低分子から生物製剤に至るまで、バイオファーマはあらゆる様式に投資を行うようになりました。規制当局は、早期承認、適応ライセンシング、コンパニオン診断の枠組みを強化しています。ヘルスケアプロバイダーは、精密さ優先のプロトコルを選択するようになってきており、一方、支払者はバイオマーカーの存在と臨床的有用性を鍵とする価値ベースの償還を受け入れています。パンデミック（世界的流行病）時代のmRNA技術の進歩とプラットフォームの適応性が、複数の治療領域にわたるパイプラインの拡大をさらに促進します。

セグメント

タイプ（モノクローナル抗体、低分子）;アプリケーション（乳がんアプリケーション、大腸がんアプリケーション、白血病アプリケーション、肺がんアプリケーション、リンパ腫アプリケーション、多発性硬化症アプリケーション、腎がんアプリケーション、湿潤型加齢黄斑変性アプリケーション、その他のアプリケーション）;販売チャネル（病院薬局、小売薬局、オンライン販売チャネル）

調査対象企業の例

• AbbVie
• Amgen
• AstraZeneca plc
• Bayer AG
• BioNTech SE
• Bristol-Myers Squibb Company
• CRISPR Therapeutics AG
• F. Hoffmann-La Roche Ltd
• Gilead Sciences, Inc.
• GlaxoSmithKline plc
• Ionis Pharmaceuticals, Inc.
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Precision NanoSystems Inc.
• Roche Holdings AG
• Sanofi
• Seagen Inc.
• Takeda Pharmaceutical Company
• Zymeworks Inc.

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Targeted Therapeutics Market to Reach US$111.8 Billion by 2030

The global market for Targeted Therapeutics estimated at US$80.5 Billion in the year 2024, is expected to reach US$111.8 Billion by 2030, growing at a CAGR of 5.6% over the analysis period 2024-2030. Monoclonal Antibodies, one of the segments analyzed in the report, is expected to record a 6.7% CAGR and reach US$73.9 Billion by the end of the analysis period. Growth in the Small Molecule segment is estimated at 3.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$21.9 Billion While China is Forecast to Grow at 9.1% CAGR

The Targeted Therapeutics market in the U.S. is estimated at US$21.9 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$22.8 Billion by the year 2030 trailing a CAGR of 9.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.7% and 5.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.7% CAGR.

Global Targeted Therapeutics Market - Key Trends & Drivers Summarized

What Makes Targeted Therapeutics a Breakthrough?

Targeted therapeutics refers to treatments designed to specifically interact with molecules or pathways that are uniquely expressed or altered in disease cells, minimizing off-target effects. This includes monoclonal antibodies, small-molecule inhibitors, antibody-drug conjugates (ADCs), gene therapy vectors with selective promoters, and emerging modalities like RNA therapeutics and peptide vaccines. Precision medicine initiatives, multi-omics profiling, and companion diagnostics support drug-development pipelines tailored to specific patient subpopulations. Pharmaceutical companies are developing ever more selective compounds targeting driver mutations (e.g., EGFR, ALK, BRAF), epigenetic regulators, and immune checkpoints. Manufacturing complexity and regulatory rigor remain high, but scalable modular platforms and adaptive clinical trial designs have reduced time-to-market.

Where Is Innovation Pushing the Envelope in Targeted Drugs?

One transformative area is bispecific antibodies that can simultaneously bind tumor antigens and immune effectors; next-generation ADCs carry dual payloads for synergistic cytotoxicity. CRISPR-based gene-editing therapies targeting somatic mutations (e.g., sickle-cell disease) are awaking as curative approaches, with mRNA lipid-nanoparticle platforms enabling tissue-specific delivery. Diagnostic evolution-liquid biopsies, digital droplet PCR, single-cell RNA-seq-is enabling real-time monitoring and adaptive dosing schemes. Computational drug-design using AI-driven target prediction is compressing discovery timelines. Integration of pharmacogenomics in electronic health records is facilitating actionable prescribing and helping avoid costly side effects.

How Are End-User Needs Shaping Therapeutic Strategies?

Oncologists favor combination regimens of targeted agents with immunotherapies to overcome resistance and improve outcomes, necessitating careful consideration of drug-drug interactions and biomarker-guided treatment. Rare-disease communities drive demand for ultra-rare targeted therapies, pushing regulatory agencies to fast-track approvals and incentivize orphan drug development. Patient-centric administration methods, like subcutaneous ADCs, home-injectable kinase inhibitors, and digital adherence systems, are gaining traction. Evidence generation through post-marketing real-world data further shapes payer acceptance, requiring drug developers to invest in value-based contracts and outcome registries. Emerging markets adopt tiered pricing and regional diagnostic labs to bridge access gaps for targeted drugs.

What’s Catalyzing the Surge in Targeted Therapeutics?

The growth in the targeted therapeutics market is driven by several factors such as the rising burden of oncology and genetic disorders, widespread adoption of biomarker-driven clinical pathways, and integration of advanced drug-delivery platforms. The emergence of scalable RNA and cell therapy manufacturing has generated biopharma investment across modalities-from small molecules to biologics. Regulatory agencies are enhancing frameworks for accelerated approvals, adaptive licensing, and companion diagnostics. Healthcare providers increasingly opt for precision-first protocols, while payers are embracing value-based reimbursements keyed to biomarker presence and clinical benefit. Pandemic-era advances in mRNA tech and platform adaptability further catalyze pipeline expansion across multiple therapeutic areas.

SCOPE OF STUDY:

The report analyzes the Targeted Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Monoclonal Antibodies, Small Molecule); Application (Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application, Renal Cancer Application, Wet Age-Related Macular Degeneration Application, Other Applications); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

• AbbVie
• Amgen
• AstraZeneca plc
• Bayer AG
• BioNTech SE
• Bristol-Myers Squibb Company
• CRISPR Therapeutics AG
• F. Hoffmann-La Roche Ltd
• Gilead Sciences, Inc.
• GlaxoSmithKline plc
• Ionis Pharmaceuticals, Inc.
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Precision NanoSystems Inc.
• Roche Holdings AG
• Sanofi
• Seagen Inc.
• Takeda Pharmaceutical Company
• Zymeworks Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Targeted Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Adoption of Precision Medicine Throws the Spotlight on Targeted Therapeutic Modalities
  • Expansion of Biomarker Discovery and Companion Diagnostics Strengthens Business Case for Targeted Drug Development
  • Growth in Oncology Pipeline Propels Demand for Tumor-Specific Targeted Treatment Platforms
  • Advancements in Monoclonal Antibodies and Antibody-Drug Conjugates Drive Innovation in Targeted Therapy
  • Integration of Genomics and AI-Driven Drug Design Enhances Precision and Efficacy of Therapies
  • High Investment in Immunotherapy and CAR-T Technologies Expands Pipeline of Targeted Immuno-Oncology Products
  • Increased Clinical Trial Success Rates for Targeted Agents Boost Stakeholder Confidence
  • Shift Toward First-Line Use of Targeted Drugs in High-Burden Diseases Sustains Market Growth
  • Rising Demand for Less Toxic Alternatives to Chemotherapy Spurs Interest in Targeted Delivery
  • Expansion of Cell and Gene Therapy Ecosystems Creates Convergence Opportunities with Targeted Therapeutics
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Targeted Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Targeted Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Targeted Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Targeted Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Monoclonal Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Monoclonal Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for Monoclonal Antibodies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Small Molecule by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Small Molecule by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for Small Molecule by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Wet Age-Related Macular Degeneration Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Wet Age-Related Macular Degeneration Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for Wet Age-Related Macular Degeneration Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Breast Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Breast Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Breast Cancer Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Colorectal Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Colorectal Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Colorectal Cancer Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Leukemia Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Leukemia Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for Leukemia Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Lung Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Lung Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 28: World 16-Year Perspective for Lung Cancer Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Lymphoma Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Lymphoma Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 31: World 16-Year Perspective for Lymphoma Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Multiple Sclerosis Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Multiple Sclerosis Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 34: World 16-Year Perspective for Multiple Sclerosis Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Renal Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Renal Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 37: World 16-Year Perspective for Renal Cancer Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 40: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 43: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 46: World 16-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Targeted Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 47: USA Recent Past, Current & Future Analysis for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: USA Historic Review for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 49: USA 16-Year Perspective for Targeted Therapeutics by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Small Molecule for the Years 2014, 2025 & 2030
  • TABLE 50: USA Recent Past, Current & Future Analysis for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: USA Historic Review for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 52: USA 16-Year Perspective for Targeted Therapeutics by Application - Percentage Breakdown of Value Sales for Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application for the Years 2014, 2025 & 2030
  • TABLE 53: USA Recent Past, Current & Future Analysis for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: USA Historic Review for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 55: USA 16-Year Perspective for Targeted Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• CANADA
  • TABLE 56: Canada Recent Past, Current & Future Analysis for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Canada Historic Review for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 58: Canada 16-Year Perspective for Targeted Therapeutics by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Small Molecule for the Years 2014, 2025 & 2030
  • TABLE 59: Canada Recent Past, Current & Future Analysis for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Canada Historic Review for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 61: Canada 16-Year Perspective for Targeted Therapeutics by Application - Percentage Breakdown of Value Sales for Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application for the Years 2014, 2025 & 2030
  • TABLE 62: Canada Recent Past, Current & Future Analysis for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Canada Historic Review for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 64: Canada 16-Year Perspective for Targeted Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• JAPAN
  • Targeted Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 65: Japan Recent Past, Current & Future Analysis for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Japan Historic Review for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 67: Japan 16-Year Perspective for Targeted Therapeutics by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Small Molecule for the Years 2014, 2025 & 2030
  • TABLE 68: Japan Recent Past, Current & Future Analysis for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Japan Historic Review for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 70: Japan 16-Year Perspective for Targeted Therapeutics by Application - Percentage Breakdown of Value Sales for Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application for the Years 2014, 2025 & 2030
  • TABLE 71: Japan Recent Past, Current & Future Analysis for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Japan Historic Review for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 73: Japan 16-Year Perspective for Targeted Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• CHINA
  • Targeted Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 74: China Recent Past, Current & Future Analysis for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: China Historic Review for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 76: China 16-Year Perspective for Targeted Therapeutics by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Small Molecule for the Years 2014, 2025 & 2030
  • TABLE 77: China Recent Past, Current & Future Analysis for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: China Historic Review for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 79: China 16-Year Perspective for Targeted Therapeutics by Application - Percentage Breakdown of Value Sales for Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application for the Years 2014, 2025 & 2030
  • TABLE 80: China Recent Past, Current & Future Analysis for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: China Historic Review for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 82: China 16-Year Perspective for Targeted Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• EUROPE
  • Targeted Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Targeted Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Targeted Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 85: Europe 16-Year Perspective for Targeted Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
  • TABLE 86: Europe Recent Past, Current & Future Analysis for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Europe Historic Review for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 88: Europe 16-Year Perspective for Targeted Therapeutics by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Small Molecule for the Years 2014, 2025 & 2030
  • TABLE 89: Europe Recent Past, Current & Future Analysis for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Europe Historic Review for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 91: Europe 16-Year Perspective for Targeted Therapeutics by Application - Percentage Breakdown of Value Sales for Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application for the Years 2014, 2025 & 2030
  • TABLE 92: Europe Recent Past, Current & Future Analysis for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Europe Historic Review for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 94: Europe 16-Year Perspective for Targeted Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• FRANCE
  • Targeted Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 95: France Recent Past, Current & Future Analysis for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: France Historic Review for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 97: France 16-Year Perspective for Targeted Therapeutics by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Small Molecule for the Years 2014, 2025 & 2030
  • TABLE 98: France Recent Past, Current & Future Analysis for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: France Historic Review for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 100: France 16-Year Perspective for Targeted Therapeutics by Application - Percentage Breakdown of Value Sales for Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application for the Years 2014, 2025 & 2030
  • TABLE 101: France Recent Past, Current & Future Analysis for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: France Historic Review for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 103: France 16-Year Perspective for Targeted Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• GERMANY
  • Targeted Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 104: Germany Recent Past, Current & Future Analysis for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Germany Historic Review for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 106: Germany 16-Year Perspective for Targeted Therapeutics by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Small Molecule for the Years 2014, 2025 & 2030
  • TABLE 107: Germany Recent Past, Current & Future Analysis for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Germany Historic Review for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 109: Germany 16-Year Perspective for Targeted Therapeutics by Application - Percentage Breakdown of Value Sales for Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application for the Years 2014, 2025 & 2030
  • TABLE 110: Germany Recent Past, Current & Future Analysis for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Germany Historic Review for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 112: Germany 16-Year Perspective for Targeted Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• ITALY
  • TABLE 113: Italy Recent Past, Current & Future Analysis for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Italy Historic Review for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 115: Italy 16-Year Perspective for Targeted Therapeutics by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Small Molecule for the Years 2014, 2025 & 2030
  • TABLE 116: Italy Recent Past, Current & Future Analysis for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Italy Historic Review for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 118: Italy 16-Year Perspective for Targeted Therapeutics by Application - Percentage Breakdown of Value Sales for Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application for the Years 2014, 2025 & 2030
  • TABLE 119: Italy Recent Past, Current & Future Analysis for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Italy Historic Review for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 121: Italy 16-Year Perspective for Targeted Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• UNITED KINGDOM
  • Targeted Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 122: UK Recent Past, Current & Future Analysis for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: UK Historic Review for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 124: UK 16-Year Perspective for Targeted Therapeutics by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Small Molecule for the Years 2014, 2025 & 2030
  • TABLE 125: UK Recent Past, Current & Future Analysis for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: UK Historic Review for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 127: UK 16-Year Perspective for Targeted Therapeutics by Application - Percentage Breakdown of Value Sales for Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application for the Years 2014, 2025 & 2030
  • TABLE 128: UK Recent Past, Current & Future Analysis for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: UK Historic Review for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 130: UK 16-Year Perspective for Targeted Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• SPAIN
  • TABLE 131: Spain Recent Past, Current & Future Analysis for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Spain Historic Review for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 133: Spain 16-Year Perspective for Targeted Therapeutics by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Small Molecule for the Years 2014, 2025 & 2030
  • TABLE 134: Spain Recent Past, Current & Future Analysis for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Spain Historic Review for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 136: Spain 16-Year Perspective for Targeted Therapeutics by Application - Percentage Breakdown of Value Sales for Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application for the Years 2014, 2025 & 2030
  • TABLE 137: Spain Recent Past, Current & Future Analysis for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Spain Historic Review for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 139: Spain 16-Year Perspective for Targeted Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• RUSSIA
  • TABLE 140: Russia Recent Past, Current & Future Analysis for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Russia Historic Review for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 142: Russia 16-Year Perspective for Targeted Therapeutics by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Small Molecule for the Years 2014, 2025 & 2030
  • TABLE 143: Russia Recent Past, Current & Future Analysis for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Russia Historic Review for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 145: Russia 16-Year Perspective for Targeted Therapeutics by Application - Percentage Breakdown of Value Sales for Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application for the Years 2014, 2025 & 2030
  • TABLE 146: Russia Recent Past, Current & Future Analysis for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Russia Historic Review for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 148: Russia 16-Year Perspective for Targeted Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• REST OF EUROPE
  • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Rest of Europe Historic Review for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 151: Rest of Europe 16-Year Perspective for Targeted Therapeutics by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Small Molecule for the Years 2014, 2025 & 2030
  • TABLE 152: Rest of Europe Recent Past, Current & Future Analysis for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Rest of Europe Historic Review for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 154: Rest of Europe 16-Year Perspective for Targeted Therapeutics by Application - Percentage Breakdown of Value Sales for Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application for the Years 2014, 2025 & 2030
  • TABLE 155: Rest of Europe Recent Past, Current & Future Analysis for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Rest of Europe Historic Review for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 157: Rest of Europe 16-Year Perspective for Targeted Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• ASIA-PACIFIC
  • Targeted Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Targeted Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 159: Asia-Pacific Historic Review for Targeted Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 160: Asia-Pacific 16-Year Perspective for Targeted Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
  • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Asia-Pacific Historic Review for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 163: Asia-Pacific 16-Year Perspective for Targeted Therapeutics by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Small Molecule for the Years 2014, 2025 & 2030
  • TABLE 164: Asia-Pacific Recent Past, Current & Future Analysis for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Asia-Pacific Historic Review for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 166: Asia-Pacific 16-Year Perspective for Targeted Therapeutics by Application - Percentage Breakdown of Value Sales for Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application for the Years 2014, 2025 & 2030
  • TABLE 167: Asia-Pacific Recent Past, Current & Future Analysis for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Asia-Pacific Historic Review for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 169: Asia-Pacific 16-Year Perspective for Targeted Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• AUSTRALIA
  • Targeted Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 170: Australia Recent Past, Current & Future Analysis for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Australia Historic Review for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 172: Australia 16-Year Perspective for Targeted Therapeutics by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Small Molecule for the Years 2014, 2025 & 2030
  • TABLE 173: Australia Recent Past, Current & Future Analysis for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Australia Historic Review for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 175: Australia 16-Year Perspective for Targeted Therapeutics by Application - Percentage Breakdown of Value Sales for Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application for the Years 2014, 2025 & 2030
  • TABLE 176: Australia Recent Past, Current & Future Analysis for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Australia Historic Review for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 178: Australia 16-Year Perspective for Targeted Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• INDIA
  • Targeted Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 179: India Recent Past, Current & Future Analysis for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: India Historic Review for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 181: India 16-Year Perspective for Targeted Therapeutics by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Small Molecule for the Years 2014, 2025 & 2030
  • TABLE 182: India Recent Past, Current & Future Analysis for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: India Historic Review for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 184: India 16-Year Perspective for Targeted Therapeutics by Application - Percentage Breakdown of Value Sales for Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application for the Years 2014, 2025 & 2030
  • TABLE 185: India Recent Past, Current & Future Analysis for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: India Historic Review for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 187: India 16-Year Perspective for Targeted Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• SOUTH KOREA
  • TABLE 188: South Korea Recent Past, Current & Future Analysis for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: South Korea Historic Review for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 190: South Korea 16-Year Perspective for Targeted Therapeutics by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Small Molecule for the Years 2014, 2025 & 2030
  • TABLE 191: South Korea Recent Past, Current & Future Analysis for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: South Korea Historic Review for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 193: South Korea 16-Year Perspective for Targeted Therapeutics by Application - Percentage Breakdown of Value Sales for Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application for the Years 2014, 2025 & 2030
  • TABLE 194: South Korea Recent Past, Current & Future Analysis for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: South Korea Historic Review for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 196: South Korea 16-Year Perspective for Targeted Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Rest of Asia-Pacific Historic Review for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 199: Rest of Asia-Pacific 16-Year Perspective for Targeted Therapeutics by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Small Molecule for the Years 2014, 2025 & 2030
  • TABLE 200: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Rest of Asia-Pacific Historic Review for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 202: Rest of Asia-Pacific 16-Year Perspective for Targeted Therapeutics by Application - Percentage Breakdown of Value Sales for Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application for the Years 2014, 2025 & 2030
  • TABLE 203: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Rest of Asia-Pacific Historic Review for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 205: Rest of Asia-Pacific 16-Year Perspective for Targeted Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• LATIN AMERICA
  • Targeted Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 206: Latin America Recent Past, Current & Future Analysis for Targeted Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 207: Latin America Historic Review for Targeted Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 208: Latin America 16-Year Perspective for Targeted Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
  • TABLE 209: Latin America Recent Past, Current & Future Analysis for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Latin America Historic Review for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 211: Latin America 16-Year Perspective for Targeted Therapeutics by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Small Molecule for the Years 2014, 2025 & 2030
  • TABLE 212: Latin America Recent Past, Current & Future Analysis for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Latin America Historic Review for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 214: Latin America 16-Year Perspective for Targeted Therapeutics by Application - Percentage Breakdown of Value Sales for Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application for the Years 2014, 2025 & 2030
  • TABLE 215: Latin America Recent Past, Current & Future Analysis for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Latin America Historic Review for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 217: Latin America 16-Year Perspective for Targeted Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• ARGENTINA
  • TABLE 218: Argentina Recent Past, Current & Future Analysis for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Argentina Historic Review for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 220: Argentina 16-Year Perspective for Targeted Therapeutics by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Small Molecule for the Years 2014, 2025 & 2030
  • TABLE 221: Argentina Recent Past, Current & Future Analysis for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Argentina Historic Review for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 223: Argentina 16-Year Perspective for Targeted Therapeutics by Application - Percentage Breakdown of Value Sales for Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application for the Years 2014, 2025 & 2030
  • TABLE 224: Argentina Recent Past, Current & Future Analysis for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Argentina Historic Review for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 226: Argentina 16-Year Perspective for Targeted Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• BRAZIL
  • TABLE 227: Brazil Recent Past, Current & Future Analysis for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Brazil Historic Review for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 229: Brazil 16-Year Perspective for Targeted Therapeutics by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Small Molecule for the Years 2014, 2025 & 2030
  • TABLE 230: Brazil Recent Past, Current & Future Analysis for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Brazil Historic Review for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 232: Brazil 16-Year Perspective for Targeted Therapeutics by Application - Percentage Breakdown of Value Sales for Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application for the Years 2014, 2025 & 2030
  • TABLE 233: Brazil Recent Past, Current & Future Analysis for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Brazil Historic Review for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 235: Brazil 16-Year Perspective for Targeted Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• MEXICO
  • TABLE 236: Mexico Recent Past, Current & Future Analysis for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Mexico Historic Review for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 238: Mexico 16-Year Perspective for Targeted Therapeutics by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Small Molecule for the Years 2014, 2025 & 2030
  • TABLE 239: Mexico Recent Past, Current & Future Analysis for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Mexico Historic Review for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 241: Mexico 16-Year Perspective for Targeted Therapeutics by Application - Percentage Breakdown of Value Sales for Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application for the Years 2014, 2025 & 2030
  • TABLE 242: Mexico Recent Past, Current & Future Analysis for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Mexico Historic Review for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 244: Mexico 16-Year Perspective for Targeted Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Rest of Latin America Historic Review for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 247: Rest of Latin America 16-Year Perspective for Targeted Therapeutics by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Small Molecule for the Years 2014, 2025 & 2030
  • TABLE 248: Rest of Latin America Recent Past, Current & Future Analysis for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Rest of Latin America Historic Review for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 250: Rest of Latin America 16-Year Perspective for Targeted Therapeutics by Application - Percentage Breakdown of Value Sales for Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application for the Years 2014, 2025 & 2030
  • TABLE 251: Rest of Latin America Recent Past, Current & Future Analysis for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Rest of Latin America Historic Review for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 253: Rest of Latin America 16-Year Perspective for Targeted Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• MIDDLE EAST
  • Targeted Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 254: Middle East Recent Past, Current & Future Analysis for Targeted Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 255: Middle East Historic Review for Targeted Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 256: Middle East 16-Year Perspective for Targeted Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
  • TABLE 257: Middle East Recent Past, Current & Future Analysis for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Middle East Historic Review for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 259: Middle East 16-Year Perspective for Targeted Therapeutics by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Small Molecule for the Years 2014, 2025 & 2030
  • TABLE 260: Middle East Recent Past, Current & Future Analysis for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Middle East Historic Review for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 262: Middle East 16-Year Perspective for Targeted Therapeutics by Application - Percentage Breakdown of Value Sales for Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application for the Years 2014, 2025 & 2030
  • TABLE 263: Middle East Recent Past, Current & Future Analysis for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Middle East Historic Review for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 265: Middle East 16-Year Perspective for Targeted Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• IRAN
  • TABLE 266: Iran Recent Past, Current & Future Analysis for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Iran Historic Review for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 268: Iran 16-Year Perspective for Targeted Therapeutics by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Small Molecule for the Years 2014, 2025 & 2030
  • TABLE 269: Iran Recent Past, Current & Future Analysis for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Iran Historic Review for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 271: Iran 16-Year Perspective for Targeted Therapeutics by Application - Percentage Breakdown of Value Sales for Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application for the Years 2014, 2025 & 2030
  • TABLE 272: Iran Recent Past, Current & Future Analysis for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Iran Historic Review for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 274: Iran 16-Year Perspective for Targeted Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• ISRAEL
  • TABLE 275: Israel Recent Past, Current & Future Analysis for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Israel Historic Review for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 277: Israel 16-Year Perspective for Targeted Therapeutics by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Small Molecule for the Years 2014, 2025 & 2030
  • TABLE 278: Israel Recent Past, Current & Future Analysis for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Israel Historic Review for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 280: Israel 16-Year Perspective for Targeted Therapeutics by Application - Percentage Breakdown of Value Sales for Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application for the Years 2014, 2025 & 2030
  • TABLE 281: Israel Recent Past, Current & Future Analysis for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Israel Historic Review for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 283: Israel 16-Year Perspective for Targeted Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• SAUDI ARABIA
  • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Saudi Arabia Historic Review for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 286: Saudi Arabia 16-Year Perspective for Targeted Therapeutics by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Small Molecule for the Years 2014, 2025 & 2030
  • TABLE 287: Saudi Arabia Recent Past, Current & Future Analysis for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Saudi Arabia Historic Review for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 289: Saudi Arabia 16-Year Perspective for Targeted Therapeutics by Application - Percentage Breakdown of Value Sales for Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application for the Years 2014, 2025 & 2030
  • TABLE 290: Saudi Arabia Recent Past, Current & Future Analysis for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Saudi Arabia Historic Review for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 292: Saudi Arabia 16-Year Perspective for Targeted Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 293: UAE Recent Past, Current & Future Analysis for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: UAE Historic Review for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 295: UAE 16-Year Perspective for Targeted Therapeutics by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Small Molecule for the Years 2014, 2025 & 2030
  • TABLE 296: UAE Recent Past, Current & Future Analysis for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: UAE Historic Review for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 298: UAE 16-Year Perspective for Targeted Therapeutics by Application - Percentage Breakdown of Value Sales for Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application for the Years 2014, 2025 & 2030
  • TABLE 299: UAE Recent Past, Current & Future Analysis for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: UAE Historic Review for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 301: UAE 16-Year Perspective for Targeted Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Rest of Middle East Historic Review for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 304: Rest of Middle East 16-Year Perspective for Targeted Therapeutics by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Small Molecule for the Years 2014, 2025 & 2030
  • TABLE 305: Rest of Middle East Recent Past, Current & Future Analysis for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Rest of Middle East Historic Review for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 307: Rest of Middle East 16-Year Perspective for Targeted Therapeutics by Application - Percentage Breakdown of Value Sales for Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application for the Years 2014, 2025 & 2030
  • TABLE 308: Rest of Middle East Recent Past, Current & Future Analysis for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Rest of Middle East Historic Review for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 310: Rest of Middle East 16-Year Perspective for Targeted Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• AFRICA
  • Targeted Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 311: Africa Recent Past, Current & Future Analysis for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Africa Historic Review for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 313: Africa 16-Year Perspective for Targeted Therapeutics by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Small Molecule for the Years 2014, 2025 & 2030
  • TABLE 314: Africa Recent Past, Current & Future Analysis for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Africa Historic Review for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 316: Africa 16-Year Perspective for Targeted Therapeutics by Application - Percentage Breakdown of Value Sales for Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application for the Years 2014, 2025 & 2030
  • TABLE 317: Africa Recent Past, Current & Future Analysis for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Africa Historic Review for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 319: Africa 16-Year Perspective for Targeted Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030

IV. COMPETITION